Immuron (IMRN) Net Cash Flow (2016 - 2024)
Immuron (IMRN) posted quarterly Net Cash Flow of -$2.6 million for Q4 2024, down 113.47% year-over-year from $19.3 million in Q1 2024, and down 113.47% quarter-over-quarter from -$1.2 million in Q4 2023.
Immuron (IMRN) Net Cash Flow (2016 - 2024) Analysis & Trends
Immuron's Net Cash Flow history runs 9 years deep, the most recent figure standing at -$2.6 million for Q4 2024.
- In Q4 2024, Net Cash Flow fell 113.47% year-over-year to -$2.6 million; the TTM figure through Sep 2025 stood at -$2.6 million (down 113.47% YoY), while the FY2025 annual figure was -$8.8 million, down 59.19% from the prior year.
- Net Cash Flow for Q4 2024 stood at -$2.6 million, down from -$1.2 million in the prior quarter.
- The five-year high for Net Cash Flow was $23.9 million in Q4 2020, with the low at -$3.1 million in Q2 2021.
- The 5-year median for Net Cash Flow is -$1.7 million (2023), against an average of $1.2 million.
- The sharpest annual moves came in 2020 and 2023: Net Cash Flow soared 8005.28% in 2020, then sank 46002.56% in 2023.
- Immuron's Net Cash Flow stood at $23.9 million in 2020, then sank by 99.96% to $8509.0 in 2021, then sank by 68.77% to $2657.0 in 2022, then tumbled by 46002.56% to -$1.2 million in 2023, then plunged by 113.47% to -$2.6 million in 2024.
- Business Quant data shows IMRN's Net Cash Flow at -$2.6 million in Q4 2024, -$1.2 million in Q4 2023, and -$1.7 million in Q2 2023.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Net Cash Flow (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 139.71 Bn | 131.86 Bn | 2.84 Bn | 652.90 Mn |
| 2 | Regeneron Pharmaceuticals | 86.87 Bn | 78.87 Bn | 3.93 Bn | -504.30 Mn |
| 3 | Argenx Se | 65.40 Bn | 60.22 Bn | 1.37 Bn | - |
| 4 | Moderna | 59.36 Bn | 54.22 Bn | 52.00 Mn | -183.00 Mn |
| 5 | BeOne Medicines | 42.12 Bn | 37.02 Bn | 1.53 Bn | 407.41 Mn |
| 6 | Alnylam Pharmaceuticals | 31.91 Bn | 28.60 Bn | 992.69 Mn | -496,000.00 |
| 7 | BioNTech SE | 28.17 Bn | 9.78 Bn | 668.28 Mn | -2.83 Bn |
| 8 | Insmed | 27.58 Bn | 26.42 Bn | 358.27 Mn | -37.14 Mn |
| 9 | Royalty Pharma | 27.33 Bn | 26.49 Bn | - | 225.59 Mn |
| 10 | Immuron | 6.64 Mn | 6.61 Mn | - | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Dec 31, 2024 | -2.60 Mn |
| Dec 31, 2024 | -2.60 Mn |
| Dec 31, 2023 | -1.22 Mn |
| Dec 31, 2023 | -1.22 Mn |
| Jun 30, 2023 | -1.73 Mn |
| Jun 30, 2023 | -1.73 Mn |
| Dec 31, 2022 | 2,657.00 |
| Dec 31, 2022 | 2,657.00 |
| Jun 30, 2022 | -2.25 Mn |
| Jun 30, 2022 | -2.25 Mn |
| Dec 31, 2021 | 8,508.98 |
| Dec 31, 2021 | 8,508.98 |
| Jun 30, 2021 | -3.14 Mn |
| Jun 30, 2021 | -3.14 Mn |
| Dec 31, 2020 | 23.89 Mn |
| Dec 31, 2020 | 23.89 Mn |
| Jun 30, 2020 | -2.06 Mn |
| Jun 30, 2020 | -2.06 Mn |
| Dec 31, 2019 | -302,214.00 |
| Dec 31, 2019 | -302,214.00 |